Understanding brain inflammation in multiple system atrophy

Interferon-gamma mediates neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy (MSA)

['FUNDING_OTHER'] · YALE UNIVERSITY · NIH-11144952

This research explores how a specific immune signal, interferon-gamma, contributes to brain damage in multiple system atrophy.

Quick facts

Phase['FUNDING_OTHER']
Study typeNih_funding
SexAll
SponsorYALE UNIVERSITY (nih funded)
Locations1 site (NEW HAVEN, UNITED STATES)
Trial IDNIH-11144952 on ClinicalTrials.gov

What this research studies

Multiple system atrophy (MSA) is a serious brain disease where a protein called alpha-synuclein builds up, leading to inflammation and damage to nerve coverings. We know that immune cells called T cells are involved, releasing a signal called interferon-gamma. This project aims to understand exactly how interferon-gamma causes inflammation and nerve damage in MSA. By studying its role, we hope to uncover new ways to protect the brain from this progressive disease.

Who could benefit from this research

Good fit: This foundational research is relevant to individuals living with multiple system atrophy, as it seeks to understand the underlying disease mechanisms.

Not a fit: Patients currently seeking direct treatment or clinical trial participation will not find immediate benefit from this basic science project.

Why it matters

Potential benefit: If successful, this work could identify new targets for treatments that slow down or stop the progression of multiple system atrophy by reducing harmful brain inflammation.

How similar studies have performed: Previous research has shown that inflammation and T cells are present in the brains of MSA patients, and preliminary results from this team suggest interferon-gamma plays a key role.

Where this research is happening

NEW HAVEN, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.